Gianantonio Saviola

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2484268/publications.pdf

Version: 2024-02-01

36 papers 459 citations

623734 14 h-index 713466 21 g-index

37 all docs

37 docs citations

37 times ranked

746 citing authors

#	Article	IF	CITATIONS
1	Long-term methotrexate use in rheumatoid arthritis patients: real-world data from the MARTE study. Minerva Medica, 2021, 112, 246-254.	0.9	2
2	Role of the osteochondral unit in the pathogenesis of osteoarthritis: focus on the potential use of clodronate. Current Rheumatology Reviews, $2021,17,.$	0.8	3
3	Acute Effects of Glucocorticoid Treatment, TNFα or IL-6R Blockade on Bone Turnover Markers and Wnt Inhibitors in Early Rheumatoid Arthritis: A Pilot Study. Calcified Tissue International, 2020, 106, 371-377.	3.1	15
4	What Do We Know About Clodronate Now? A Medical and Veterinary Perspective. Journal of Equine Veterinary Science, 2020, 88, 102874.	0.9	5
5	Bone fracture risk: Density and microarchitecture qualification. Materials Today: Proceedings, 2020, 32, 93-97.	1.8	O
6	BESTEST analysis in patients with normal or osteopenic DEXA. Minerva Medica, 2020, 110, 597-599.	0.9	0
7	Use of clodronate for painful knee prosthesis in osteoarthritis patients: a 6-month pilot study. Minerva Medica, 2020, 111, 551-559.	0.9	3
8	Physical Activity Prevents Cartilage Degradation: A Metabolomics Study Pinpoints the Involvement of Vitamin B6. Cells, 2019, 8, 1374.	4.1	10
9	Complete clinical and functional recovery following low-dose methotrexate related paraparesis in a patient with compound c.1298A>C AND c.677C>T MTHFR polymorphism. Medicine (United States), 2018, 97, e13350.	1.0	3
10	Clodronate in the management of different musculoskeletal conditions. Minerva Medica, 2018, 109, 300-325.	0.9	21
11	Intramuscular clodronate in erosive osteoarthritis of the hand is effective on pain and reduces serum COMP: a randomized pilot trial—The ER.O.D.E. study (ERosive Osteoarthritis and) Tj ETQq1 1 0.784314	rg B I2/Ove	rlo ek 10 Tf 50
12	AB0429â€Short-term effects of low dose glucocorticoids on bone metabolism in early rheumatoid arthritis., 2017,,.		0
13	Prevalence and incidence of osteoporotic fractures in patients on long-term glucocorticoid treatment for rheumatic diseases: the Glucocorticoid Induced OsTeoporosis TOol (GIOTTO) study. Reumatismo, 2017, 69, 30.	0.9	36
14	Correlations between immunogenicity, drug levels, and disease activity in an Italian cohort of rheumatoid arthritis patients treated with tocilizumab. Biologics: Targets and Therapy, 2016, 10, 53.	3.2	17
15	Densitometric evaluation might prevent failure of knee artroplasty for aseptic loosening. Journal of King Abdulaziz University, Islamic Economics, 2016, 37, 212-214.	1.1	2
16	Multifocal osteonecrosis in a patient with anamnestic ulcerative colitis. Is there a relationship with the disease and the use of glucocorticoids twenty years before? A brief review of the literature. Clinica Terapeutica, 2016, 167, 121-3.	0.3	0
17	Atypical femoral fracture as first sign of non-hodgkin lymphoma- case report with a brief review of the literature. Clinica Terapeutica, 2016, 167, 188-190.	0.3	3
18	Can Febuxostat Reduce Triglyceride and Cholesterol Serum Levels in Gouty Patients?. Journal of Clinical Rheumatology, 2014, 20, 394-395.	0.9	7

#	Article	IF	CITATIONS
19	Clarithromycin in rheumatoid arthritis: the addition to methotrexate and low-dose methylprednisolone induces a significant additive value—a 24-month single-blind pilot study. Rheumatology International, 2013, 33, 2833-2838.	3.0	11
20	THU0113 Predictive factors of response to rituximab therapy modify the accelerated atherosclerosis in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 2013, 71, 192.2-192.	0.9	0
21	Factors correlated with improvement of endothelial dysfunction during rituximab therapy in patients with rheumatoid arthritis. Biologics: Targets and Therapy, 2013, 7, 69.	3.2	31
22	No Correlations Between the Development of Specific IgA and IgM Antibodies Against Anti-TNF Blocking Agents, Disease Activity and Adverse Side Reactions in Patients with Rheumatoid Arthritis. Open Rheumatology Journal, 2013, 7, 75-80.	0.2	7
23	Clodronate and hydroxychloroquine in erosive osteoarthritis: a 24-month open randomized pilot study. Modern Rheumatology, 2012, 22, 256-263.	1.8	34
24	Clodronate and hydroxychloroquine in erosive osteoarthritis: a 24-month open randomized pilot study. Modern Rheumatology, 2012, 22, 256-263.	1.8	33
25	Determinants of Risk Infection During Therapy with Anti TNF-Alpha Blocking Agents in Rheumatoid Arthritis. Open Rheumatology Journal, 2012, 6, 33-37.	0.2	12
26	Efficacy and Safety of Leflunomide or Methotrexate plus Subcutaneous Tumour Necrosis Factor-Alpha Blocking Agents in Rheumatoid Arthritis. International Journal of Immunopathology and Pharmacology, 2011, 24, 269-274.	2.1	21
27	Cost-effectiveness treatment with Rituximab in patients with rheumatoid arthritis in real life. Rheumatology International, 2011, 31, 1465-1469.	3.0	10
28	Can clodronate be effective in the treatment of disabling hydroxyapatite crystal-deposition disease? A report of two cases. Rheumatology International, 2011, 31, 415-417.	3.0	4
29	Cost Effectiveness Analysis of Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis. A Systematic Review Literature. International Journal of Rheumatology, 2011, 2011, 1-6.	1.6	32
30	Clarithromycin in adult-onset Still's disease: a study of 6 cases. Rheumatology International, 2010, 30, 555-560.	3.0	14
31	The Economic Burden of Biological Therapy in Rheumatoid Arthritis in Clinical Practice: Cost-Effectiveness Analysis of Sub-Cutaneous Anti-TNFα Treatment in Italian Patients. International Journal of Immunopathology and Pharmacology, 2009, 22, 1147-1152.	2.1	20
32	Early Rheumatoid Arthritis in Italy: study of incidence based on a two-level strategy in a sub-area of Florence (Scandicci-Le Signe). Rheumatology International, 2008, 28, 777-781.	3.0	15
33	Improved rheumatoid digital vasculitis in a patient treated with TNFα agent blocking (infliximab). Rheumatology International, 2008, 28, 1253-1255.	3.0	9
34	Comments on: Effects of clarithromycin in patients with active rheumatoid arthritis. Current Medical Research and Opinion, 2007, 23, 2763-2764.	1.9	3
35	Compared clinical efficacy and bone metabolic effects of low-dose deflazacort and methyl prednisolone in male inflammatory arthropathies: a 12-month open randomized pilot study. Rheumatology, 2007, 46, 994-998.	1.9	22
36	Anti-nucleosome antibodies as prediction factor of development of autoantibodies during therapy with three different TNFα blocking agents in rheumatoid arthritis. Clinical Rheumatology, 2007, 27, 91-95.	2.2	26